


About Spherix Global Insights

Spherix is the world’s leading Life Sciences market intelligence and advisory services firm, providing unrivaled knowledge and the most informed, actionable insights.

We bring human intelligence to market intelligence. Spherix empowers customers to access critical insights that drive successful decision-making through deep, expert knowledge.



Spherix Provides Independent Expertise in Seven Areas



Dermatology



Nephrology



Gastroenterology



Neurology



Rheumatology



Ophthalmology



Hematology/Oncology

This is a guide to the publications Spherix will produce in 2024. It is organized by therapeutic area, indication, and deliverable.

Going Beyond the Data

The report is only the beginning. Spherix brings curation and interpretation to market intelligence, working closely with customers to reveal actionable insights that transform markets.

Type of Publications	
MARKET DYNAMIX	A yearly market overview of an indication, Market Dynamix provides insights into current treatment paradigms and unmet patient needs as well as physician opinions on how they will likely prescribe new products upon approval.
REALTIME DYNAMIX	A US quarterly or EU5 semi-annual update on an indication, RealTime Dynamix provides trending content on brand use, future intentions, promotional activity, disease awareness and controversy, and pipeline product perceptions.
LAUNCH DYNAMIX	Published monthly, Launch Dynamix tracks a new brand’s first eighteen months of commercial availability. Each quarter includes a deep dive into promotional activity, barriers to uptake, and patient types gravitating to the launch brand.
PATIENT CHART DYNAMIX	A yearly large-scale patient chart audit on an indication, Patient Chart Dynamix unmaskes real patient management patterns and uncovers the “why” behind treatment decisions.
PATIENT VOICE DYNAMIX	An independent service that explores the voice of the patient as they progress through their disease and treatment journeys.
PAYER DYNAMIX	Empowers pharmaceutical companies with forward-looking insights from key payer decision makers – enabling market access, brand, and strategy teams to confidently navigate evolving coverage and reimbursement landscapes, while preparing for potential policy-driven disruptions.
SPECIAL TOPIX	Whether the focus is breaking industry news, ongoing trends, conference coverage, or quick-pulse reactions, Special Topix assesses the impact of events in our specialty markets.
For a complete index of available reports, visit www.clientportal.spherixglobalinsights.com	



Alopecia Areata

MARKET DYNAMIX	<ul style="list-style-type: none">Alopecia Areata, USAlopecia Areata, EU5*Alopecia Areata, JP*Alopecia Areata, CH*
LAUNCH DYNAMIX	<ul style="list-style-type: none">Leqselvi (SUN Pharma) in Alopecia Areata, USLitfulo (Pfizer) in Alopecia Areata, US

Atopic Dermatitis

MARKET DYNAMIX	<ul style="list-style-type: none">Atopic Dermatitis, USAtopic Dermatitis, JP*
REALTIME DYNAMIX	<ul style="list-style-type: none">Atopic Dermatitis, EU5Atopic Dermatitis, JP/ CH
LAUNCH DYNAMIX	<ul style="list-style-type: none">Ebglyss (Eli Lilly) in Atopic Dermatitis, USNemluvio (Galderma) in Atopic Dermatitis, USVtama and Zoryve (Organon/ Arcutis) in Atopic Dermatitis, US
PATIENT CHART DYNAMIX	<ul style="list-style-type: none">Atopic Dermatitis, US
PATIENT VOICE DYNAMIX	<ul style="list-style-type: none">Atopic Dermatitis, US*

Chronic Spontaneous Urticaria

MARKET DYNAMIX	<ul style="list-style-type: none">Chronic Spontaneous Urticaria, US
PATIENT CHART DYNAMIX	<ul style="list-style-type: none">Chronic Spontaneous Urticaria, US*
PATIENT VOICE DYNAMIX	<ul style="list-style-type: none">Chronic Spontaneous Urticaria, US*

Other Dermatology Indications

MARKET DYNAMIX	<ul style="list-style-type: none">Asthma, USPrurigo Nodularis, US
LAUNCH DYNAMIX	<ul style="list-style-type: none">Dupixent (Sanofi/Regeneron) in Chronic Spontaneous Urticaria, USDupixent (Sanofi/Regeneron) in Chronic Obstructive Pulmonary Disease, USRemibrutinib (Novartis) in Chronic Spontaneous Urticaria, USNemluvio (Galderma) in Prurigo Nodularis, US
SPECIAL TOPI	<ul style="list-style-type: none">Biologic Coordinators Across Dermatology, US

Hidradenitis Suppurativa

MARKET DYNAMIX	<ul style="list-style-type: none">Hidradenitis Suppurativa, US
REALTIME DYNAMIX	<ul style="list-style-type: none">Hidradenitis Suppurativa, EU5
LAUNCH DYNAMIX	<ul style="list-style-type: none">Bimzelx (UCB) in Hidradenitis Suppurativa, USCosentyx (Novartis) in Hidradenitis Suppurativa, US
PATIENT CHART DYNAMIX	<ul style="list-style-type: none">Hidradenitis Suppurativa, US*

Plaque Psoriasis

REALTIME DYNAMIX	<ul style="list-style-type: none">Plaque Psoriasis, USPlaque Psoriasis, EU5
LAUNCH DYNAMIX	<ul style="list-style-type: none">Bimzelx (UCB) in Plaque Psoriasis, USIchotrokinra (J&J) in Plaque Psoriasis, US*
PATIENT CHART DYNAMIX	<ul style="list-style-type: none">Plaque Psoriasis, US
PATIENT VOICE DYNAMIX	<ul style="list-style-type: none">Plaque Psoriasis, US*
SPECIAL TOPI	<ul style="list-style-type: none">The Oral Opportunity in Plaque Psoriasis, US

Vitiligo

MARKET DYNAMIX	<ul style="list-style-type: none">Vitiligo, USVitiligo, EU5Vitiligo, JP*Vitiligo, CH*
----------------	--

Cross Specialty

SPECIAL TOPI	<ul style="list-style-type: none">Awareness and Expected Impact of IRA Changes in 2025Payer Management Strategies, US
--------------	--

Key

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
PAYER DYNAMIX	Payer priorities and tactics compared across therapy areas
SPECIAL TOPI	Current events on specific interest areas

Eosinophilic Esophagitis

MARKET DYNAMIX	<ul style="list-style-type: none"> Eosinophilic Esophagitis, US Eosinophilic Esophagitis, EU5 (2025 only)
----------------	---

Inflammatory Bowel Disease

REALTIME DYNAMIX	<ul style="list-style-type: none"> Crohn's Disease, US Crohn's Disease, EU5 Crohn's Disease, JP+ Ulcerative Colitis, US Ulcerative Colitis, EU5 Ulcerative Colitis, JP+
LAUNCH DYNAMIX	<ul style="list-style-type: none"> Tremfya (Janssen) in Crohn's Disease, US Omvoh (Eli Lilly) in Crohn's Disease, US Skyrizi (AbbVie) in Ulcerative Colitis, US Tremfya (Janssen) in Ulcerative Colitis, US
PATIENT CHART DYNAMIX	<ul style="list-style-type: none"> Inflammatory Bowel Disease New Starts, US+ Inflammatory Bowel Disease Switching, US Inflammatory Bowel Disease Switching, EU5
PATIENT VOICE DYNAMIX	<ul style="list-style-type: none"> Inflammatory Bowel Disease, US+
SPECIAL TOPIX	<ul style="list-style-type: none"> Biologic Coordinators in Gastroenterology, US The Role of APPs in IBD+

Obesity

MARKET DYNAMIX	<ul style="list-style-type: none"> Obesity, US+
LAUNCH DYNAMIX	<ul style="list-style-type: none"> Oral Semaglutide (Novo Nordisk) in Obesity, US+ Orforglipron (Eli Lilly) in Obesity, US+ CagriSema (Novo Nordisk) in Obesity, US+

MASH

MARKET DYNAMIX	<ul style="list-style-type: none"> MASH, US MASH, EU5 (2025 only)
LAUNCH DYNAMIX	<ul style="list-style-type: none"> Rezdiffra (Madrigal) in MASH, US (2025 only) Wegovy (Novo Nordisk) in MASH, US
PATIENT CHART DYNAMIX	<ul style="list-style-type: none"> MASH, US+
SPECIAL TOPIX	<ul style="list-style-type: none"> MASH Screening and Management among PCPs and Endocrinologists, US+

Other Gastroenterology Indications

MARKET DYNAMIX	<ul style="list-style-type: none"> Celiac Disease, US Primary Biliary Cholangitis/ Primary Sclerosing Cholangitis, US
REALTIME DYNAMIX	<ul style="list-style-type: none"> Irritable Bowel Syndrome, US
LAUNCH DYNAMIX	<ul style="list-style-type: none"> Iqirvo (Ipsen) in Primary Biliary Cholangitis, US Linerixibat (GSK) in Cholestatic Pruritus Among PBC Patients, US+ Livdelzi (Gilead/ Cymabay) in Primary Biliary Cholangitis, US
SPECIAL TOPIX	<ul style="list-style-type: none"> Biologic Coordinators in Gastroenterology, US The Business of Gastroenterology, US+

Cross Specialty

SPECIAL TOPIX	<ul style="list-style-type: none"> Awareness and Expected Impact of IRA Changes in 2025 Payer Management Strategies, US
---------------	---

Key

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
PAYER DYNAMIX	Payer priorities and tactics compared across therapy areas
SPECIAL TOPIX	Current events on specific interest areas

*Pending approvals and launch



2025 & 2026 Rheumatology Publications

Lupus

MARKET DYNAMIX	<ul style="list-style-type: none"> Cutaneous Lupus, US Systemic Lupus Erythematosus, US Systemic Lupus Erythematosus Pipeline Refresh, US Systemic Lupus Erythematosus, EU5 Lupus Nephritis, China*
REALTIME DYNAMIX	<ul style="list-style-type: none"> Lupus Nephritis, US Lupus Nephritis, EU5 Lupus Nephritis, Brazil* Lupus Nephritis, Canada*
LAUNCH DYNAMIX	<ul style="list-style-type: none"> Gazyva (Genentech) in Lupus Nephritis, US
PATIENT CHART DYNAMIX	<ul style="list-style-type: none"> Lupus Nephritis, US Moderate to Severe SLE, US Systemic Lupus Erythematosus & Lupus Nephritis, EU5* Cutaneous Lupus, US*
PATIENT VOICE DYNAMIX	<ul style="list-style-type: none"> Systemic Lupus Erythematosus & Lupus Nephritis, US*

Spondyloarthritis (AS, nr-AxSpA, and PsA)

MARKET DYNAMIX	<ul style="list-style-type: none"> Ankylosing Spondylitis & nr-AxSpA, US Ankylosing Spondylitis & nr-AxSpA, EU5 Psoriatic Arthritis, EU5
REALTIME DYNAMIX	<ul style="list-style-type: none"> Psoriatic Arthritis, US
LAUNCH DYNAMIX	<ul style="list-style-type: none"> Bimzelx (UCB) in AS & nr-AxSpA, US Bimzelx (UCB) in Psoriatic Arthritis, US Sotyktu (BMS) in Psoriatic Arthritis, US**

Other Rheumatology Indications

MARKET DYNAMIX	<ul style="list-style-type: none"> Idiopathic Inflammatory Myopathies, US PMR and GCA Pipeline Refresh, US* Rheumatoid Arthritis, US Rheumatoid Arthritis, EU5 Sjogren's Disease, US Systemic Sclerosis, US
LAUNCH DYNAMIX	<ul style="list-style-type: none"> Rinvoq (AbbVie) in Giant Cell Arteritis, US Brepocitinib in Dermatomyositis, US** Ianalumab in Sjogren's Disease, US**
PATIENT VOICE DYNAMIX	<ul style="list-style-type: none"> Systemic Sclerosis, US*
SPECIAL TOPIX	<ul style="list-style-type: none"> ILD in Rheumatology, US Cell Therapy in Rheumatology, US Biologic Coordinators Across Rheumatology, US*

Cross Specialty

SPECIAL TOPIX	<ul style="list-style-type: none"> Payer Management Strategies, US
---------------	---

Key

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
PAYER DYNAMIX	Payer priorities and tactics compared across therapy areas
SPECIAL TOPIX	Current events on specific interest areas



2025 & 2026 Nephrology Publications

Glomerular Diseases

MARKET DYNAMIX	<ul style="list-style-type: none">Focal Segmental Glomerulosclerosis, US⁺Membranous Nephropathy, USAPOL-mediated kidney disease, US⁺
REALTIME DYNAMIX	<ul style="list-style-type: none">IgA Nephropathy, USIgA Nephropathy, EU5
LAUNCH DYNAMIX	<ul style="list-style-type: none">Fabhalta (Novartis) in C3G, USEmpaveli (Apellis) in C3G, USFilspari in FSGS*Fabhalta (Novartis) in IgAN, USVanrafia (Novartis) in IgAN, USSibeprenlimab (Otsuka) in IgAN, USAtacicept (Vera) in IgAN, US*Povetacicept (Vertex) in IgAN US*
PATIENT CHART DYNAMIX	<ul style="list-style-type: none">Focal Segmental Glomerulosclerosis, USIgA Nephropathy, USIgA Nephropathy, EU5IgA Nephropathy, JapanIgA Nephropathy, ChinaComplement 3 Glomerulopathy, US
PATIENT VOICE DYNAMIX	<ul style="list-style-type: none">IgA Nephropathy, US

Cross Specialty

SPECIAL TOPI	<ul style="list-style-type: none">Awareness and Expected Impact of IRA Changes in 2025, USPayer Management Strategies, US
--------------	--

Kidney Disease

MARKET DYNAMIX	<ul style="list-style-type: none">ADPKD, USTransplant Rejection, US
REALTIME DYNAMIX	<ul style="list-style-type: none">Dialysis, EU5Dialysis, US, Nephrologists, NP/PAs, USDialysis, Renal Dietitians, USHyperkalemia, US
LAUNCH DYNAMIX	<ul style="list-style-type: none">Xphozah (Ardelyx) in Hyperphosphatemia, USVafseo (Akebia) in Renal Anemia, USOLC (Unicycive) in Hyperphosphatemia, US*
PATIENT CHART DYNAMIX	<ul style="list-style-type: none">Chronic Kidney Disease, Non-Dialysis, nephrologists, USChronic Kidney Disease, Non-Dialysis, PCPsDialysis, US
SPECIAL TOPI	<ul style="list-style-type: none">Multispecialty (Nephrology & Hematology) Approach to aHUS, USImplications of the Dialysis Bundle, USASN Kidney Week Conference, USBuy and Bill in Nephrology Practices, USReactions to Updated KDIGO Guidelines, US
PATIENT VOICE DYNAMIX	<ul style="list-style-type: none">Chronic Kidney Disease, US

Lupus Nephritis

REALTIME DYNAMIX	<ul style="list-style-type: none">Lupus Nephritis, USLupus Nephritis, EU5
PATIENT CHART DYNAMIX	<ul style="list-style-type: none">Lupus Nephritis, US

Key

LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
PAYER DYNAMIX	Payer priorities and tactics compared across therapy areas
SPECIAL TOPI	Current events on specific interest areas



Alzheimer's Disease

MARKET DYNAMIX	<ul style="list-style-type: none">Alzheimer's Disease, US: Focus on Diagnostic Pathway (Q2)Alzheimer's Disease, US: Focus on Pipeline (Q4)
REALTIME DYNAMIX	<ul style="list-style-type: none">Alzheimer's Disease, 2 Wave, US*
LAUNCH DYNAMIX	<ul style="list-style-type: none">Leqembi (Eisai/Biogen) in Alzheimer's Disease, USKisunla (Eli Lilly) in Alzheimer's Disease, USSemaglutide in Alzheimer's Disease, US
PATIENT CHART DYNAMIX	<ul style="list-style-type: none">Alzheimer's Disease, US
PATIENT VOICE DYNAMIX	<ul style="list-style-type: none">Alzheimer's Disease, US*

Migraine

REALTIME DYNAMIX	<ul style="list-style-type: none">Migraine, US (2025)Migraine, 2 Wave, US*
LAUNCH DYNAMIX	<ul style="list-style-type: none">Zavzpret (Pfizer) in Acute Migraine, US
PATIENT CHART DYNAMIX	<ul style="list-style-type: none">Migraine, US*

Multiple Sclerosis

MARKET DYNAMIX	<ul style="list-style-type: none">Multiple Sclerosis, US: Focus on Current Market Landscape (Q1)Multiple Sclerosis, US: Focus on Pipeline Opportunities (Q3)
REALTIME DYNAMIX	<ul style="list-style-type: none">Multiple Sclerosis- 2 Wave, US*
LAUNCH DYNAMIX	<ul style="list-style-type: none">Tolebrutinib, (Sanofi) nrSPMS, US*

Psychiatric Indications

MARKET DYNAMIX	<ul style="list-style-type: none">Bipolar Disease, US*Major Depressive Disorder (MDD), US*Schizophrenia, US*
----------------	---

Generalized Myasthenia Gravis

REALTIME DYNAMIX	<ul style="list-style-type: none">Generalized Myasthenia Gravis, USGeneralized Myasthenia Gravis, EU5*
LAUNCH DYNAMIX	<ul style="list-style-type: none">Uplizna, (Amgen) Generalized Myasthenia Gravis (gMG), USImaavy, (J&J) Generalized Myasthenia Gravis (gMG), USBiosimilar eculizumab in Generalized Myasthenia Gravis, USGefurulimab, (Alexion/AZ) Generalized Myasthenia Gravis (gMG), US*Cemdisiran, (Regeneron) Generalized Myasthenia Gravis (gMG), US*
PATIENT CHART DYNAMIX	<ul style="list-style-type: none">Generalized Myasthenia Gravis, US
PATIENT VOICE DYNAMIX	<ul style="list-style-type: none">Generalized Myasthenia Gravis, US*

Other Neurology Indications

MARKET DYNAMIX	<ul style="list-style-type: none">Chronic Inflammatory Demyelinating Polyneuropathy, USEpilepsy, USHuntington's Disease, US*Parkinson's Disease, US*
SPECIAL TOPIX	<ul style="list-style-type: none">Neurology Pipeline Opportunities, USPractice Dynamix in Neurology, USCell Therapy in Neurology Indications, US*

Cross Specialty

SPECIAL TOPIX	<ul style="list-style-type: none">Payer Management Strategies, US
---------------	---

Key

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
PAYER DYNAMIX	Payer priorities and tactics compared across therapy areas
SPECIAL TOPIX	Current events on specific interest areas



Diabetic Macular Edema

MARKET DYNAMIX	• Diabetic Macular Edema, US⁺
REALTIME DYNAMIX	• <i>Diabetic Macular Edema, US</i>
LAUNCH DYNAMIX	• <i>Pavblu in Diabetic Macular Edema, US</i>
PATIENT CHART DYNAMIX	• <i>Diabetic Macular Edema, US</i>

Neovascular Age-Related Macular Degeneration

REALTIME DYNAMIX	• <i>Neovascular Age-Related Macular Degeneration, US</i>
LAUNCH DYNAMIX	• <i>Pavblu in Neovascular Age-Related Macular Degeneration, US</i>
PATIENT CHART DYNAMIX	• <i>Neovascular Age-Related Macular Degeneration, US</i>

Other Ophthalmology Indications

MARKET DYNAMIX	<ul style="list-style-type: none">• Geographic Atrophy, US• Glaucoma, US• Thyroid Eye Disease (TED), US• Age-Related Macular Degeneration, US⁺• Diabetic Retinopathy, US⁺• Dry Eye Syndrome, US⁺• Glaucoma, US⁺• Uveitis, US⁺
LAUNCH DYNAMIX	• <i>Pavblu in Diabetic Retinopathy, US</i>
SPECIAL TOPIX	<ul style="list-style-type: none">• Gene Therapies in Retina, US• Pipeline Opportunities in Ophthalmology, US

Cross Specialty

SPECIAL TOPIX	• <i>Payer Management Strategies, US</i>
---------------	--

Key

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
PAYER DYNAMIX	Payer priorities and tactics compared across therapy areas
SPECIAL TOPIX	Current events on specific interest areas



2025 & 2026 Hematology/Oncology Publications



B-Cell Malignancies	
MARKET DYNAMIX	<ul style="list-style-type: none">Large B-Cell Lymphoma, EU5⁺Chronic Lymphocytic Leukemia, US⁺
REALTIME DYNAMIX	<ul style="list-style-type: none">Large B-Cell Lymphoma, US⁺
PATIENT CHART DYNAMIX	<ul style="list-style-type: none">Large B-Cell Lymphoma, EU5⁺Chronic Lymphocytic Leukemia, US⁺
PATIENT VOICE DYNAMIX	<ul style="list-style-type: none">B-Cell Malignancies, US⁺
Bleeding Disorders	
MARKET DYNAMIX	<ul style="list-style-type: none">Hemophilia, USHemophilia, EU5Von Willebrand Disease, US⁺
LAUNCH DYNAMIX	<ul style="list-style-type: none">Alhemo in Hemophilia A & BHypnavzi in Hemophilia A & BQfitlia in Hemophilia A & B
PATIENT CHART DYNAMIX	<ul style="list-style-type: none">Hemophilia A & B⁺
PATIENT VOICE DYNAMIX	<ul style="list-style-type: none">Hemophilia A & B⁺
SPECIAL TOPI	<ul style="list-style-type: none">Women, Girls, and People who have or had the Potential to Menstruate (WGPPM) and Bleeding Disorders⁺
Hemoglobinopathies	
MARKET DYNAMIX	<ul style="list-style-type: none">Sickle Cell DiseaseThalassemia
LAUNCH DYNAMIX	<ul style="list-style-type: none">Mitapivat in Thalassemia^{**}
PATIENT CHART DYNAMIX	<ul style="list-style-type: none">Sickle Cell DiseaseThalassemia
PATIENT VOICE DYNAMIX	<ul style="list-style-type: none">Sickle Cell Disease⁺
Multi-Indication	
PAYER DYNAMIX	<ul style="list-style-type: none">Cell and Gene Therapy, US⁺

Multiple Myeloma	
MARKET DYNAMIX	<ul style="list-style-type: none">Multiple Myeloma, EU5⁺
REALTIME DYNAMIX	<ul style="list-style-type: none">Multiple Myeloma, US
PATIENT CHART DYNAMIX	<ul style="list-style-type: none">Multiple Myeloma, US⁺
PATIENT VOICE DYNAMIX	<ul style="list-style-type: none">Multiple Myeloma, US⁺
Myelodysplastic Syndrome	
MARKET DYNAMIX	<ul style="list-style-type: none">Myelodysplastic Syndrome, US⁺
Paroxysmal Nocturnal Hemoglobinuria	
MARKET DYNAMIX	<ul style="list-style-type: none">Paroxysmal Nocturnal Hemoglobinuria, EU5
REALTIME DYNAMIX	<ul style="list-style-type: none">Paroxysmal Nocturnal Hemoglobinuria, US
PATIENT CHART DYNAMIX	<ul style="list-style-type: none">Paroxysmal Nocturnal Hemoglobinuria, US
Other Benign Hematology Indications	
MARKET DYNAMIX	<ul style="list-style-type: none">Immune Thrombocytopenic Purpura (ITP)Warm Autoimmune Hemolytic Anemia (w-AIHA)
LAUNCH DYNAMIX	<ul style="list-style-type: none">Nipocalimab in w-AIHA^{**}Rilzabrutinib in ITP^{**}
SPECIAL TOPI	<ul style="list-style-type: none">Adoption and Impact of Gene Therapy in HematologyMultispecialty (Nephrology & Hematology) Approach to Atypical Hemolytic Uremic Syndrome (aHUS), US
Cross Specialty	
SPECIAL TOPI	<ul style="list-style-type: none">Payer Management Strategies, US

Key

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
PAYER DYNAMIX	Payer priorities and tactics compared across therapy areas
SPECIAL TOPI	Current events on specific interest areas

*Pending approvals and launch

* New in 2026

Publications may change due to factors such as FDA approval status and other market events



Looking for more? Visit the Spherix Portal

The Spherix Portal helps clients interact with their data and insights so they can find answers to their important questions.

By using the portal, Spherix clients can access all their subscribed data and easily integrate intelligence into their research projects.

Access to the Spherix Portal is open to anyone. It's the best way to find the right product to fit your needs.

Create your free account at
www.clientportal.spherixglobalinsights.com